Diabetes medications and cardiovascular outcome trials: Lessons learned

被引：11
|
作者：
Patel, Kershaw V. [1 ]
Rocha, Natalia de Albuquerque [1 ]
McGuire, Darren K. [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Cardiol, Dallas, TX USA
来源：
CLEVELAND CLINIC JOURNAL OF MEDICINE | 2017年 / 84卷 / 10期
关键词：
HEART-FAILURE; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; TYPE-2; SITAGLIPTIN; MELLITUS; INHIBITION; EXENATIDE; IMPROVES; COTRANSPORTERS;
D O I：
10.3949/ccjm.84gr.17006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.
引用
收藏
页码：759 / 767
页数：9
相关论文
共 50 条
  • [21] Travelling with medications - Some lessons learned
    Beran, Roy G.
    Docking, James
    AUSTRALIAN FAMILY PHYSICIAN, 2007, 36 (05) : 349 - 351
  • [22] Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials
    Cotter, Gad
    Davison, Beth A.
    Edwards, Christopher
    Senger, Stefanie
    Teerlink, John R.
    Zannad, Faiez
    Nielsen, Olav Wendelboe
    Metra, Marco
    Mebazaa, Alexandre
    Chioncel, Ovidiu
    Greenberg, Barry H.
    Maggioni, Aldo P.
    Ertl, Georg
    Sato, Naoki
    Cohen-Solal, Alain
    AMERICAN HEART JOURNAL, 2021, 240 : 73 - 80
  • [23] Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
    Darren K. McGuire
    Silvio E. Inzucchi
    Odd Erik Johansen
    Julio Rosenstock
    Jyothis T. George
    Nikolaus Marx
    Journal of Pharmaceutical Policy and Practice, 14
  • [24] Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
    McGuire, Darren K.
    Inzucchi, Silvio E.
    Johansen, Odd Erik
    Rosenstock, Julio
    George, Jyothis T.
    Marx, Nikolaus
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2021, 14 (01)
  • [25] Lessons learned from lifestyle prevention trials in gestational diabetes mellitus
    Egan, A. M.
    Simmons, D.
    DIABETIC MEDICINE, 2019, 36 (02) : 142 - 150
  • [26] Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
    Hinnen, Deborah
    Kruger, Davida F.
    DIABETES METABOLIC SYNDROME AND OBESITY, 2019, 12 : 447 - 454
  • [27] Research digest: more cardiovascular outcome trials in diabetes
    Sattar, Naveed
    Preiss, David
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (09): : 687 - 687
  • [28] A review of cardiovascular outcome trials in type 2 diabetes
    Cypryk, Katarzyna
    Malecki, Piotr
    ENDOKRYNOLOGIA POLSKA, 2018, 69 (04) : 424 - 431
  • [29] CARDIOVASCULAR OUTCOME TRIALS-WHAT HAVE WE LEARNED FROM?
    Guja, Cristian
    INTERDIAB 2017: DIABETES MELLITUS IN INTERNAL MEDICINE, 2017, : 31 - 38
  • [30] Non-inferiority study design: lessons to be learned from cardiovascular trials
    Head, Stuart J.
    Kaul, Sanjay
    Bogers, Ad J. J. C.
    Kappetein, A. Pieter
    EUROPEAN HEART JOURNAL, 2012, 33 (11) : 1318 - 1324
12345